01.25.07
SommaTech Consulting has entered into a strategic collaboration with Pharmaceutical Technologies International, Inc. (PTI) to help achieve FDA-regulated product goals. PTI is a developer of tablet formulation systems and compaction simulation technology, which enables formulators to analyze and characterize the tabletability properties of new APIs.
Compaction profile assessments address the variability of a new formulation, offering a greater focus for validation and determination of key tablet properties. This technology also matches compaction profiles of various tablet machines at different speeds, simulating behavior during large-scale manufacture and providing performance predictions, which help to resolve potential manufacturing issues.
"We are very pleased to partner with PTI Inc. to offer clients access to formulation design and characterization studies which analyze and identify potential performance issues early in the drug formulation process," said Russell Somma, Ph.D., president. "For our clients to achieve their product goals, rapid commercialization of process into the production environment is mandatory. Together, SommaTech and PTI Inc., deliver affordable, innovative solutions that positively impact the drug development process, ultimately accelerating product entry into the market."
"How companies leverage new developments can help them break through process barriers to realize substantial competitive advantages," stated Metin Celik, Ph.D., president, PTI. "SommaTech and PTI, Inc. bring deep industry experience and technological innovation to help clients reduce the amount of time to reach peak sales."
Compaction profile assessments address the variability of a new formulation, offering a greater focus for validation and determination of key tablet properties. This technology also matches compaction profiles of various tablet machines at different speeds, simulating behavior during large-scale manufacture and providing performance predictions, which help to resolve potential manufacturing issues.
"We are very pleased to partner with PTI Inc. to offer clients access to formulation design and characterization studies which analyze and identify potential performance issues early in the drug formulation process," said Russell Somma, Ph.D., president. "For our clients to achieve their product goals, rapid commercialization of process into the production environment is mandatory. Together, SommaTech and PTI Inc., deliver affordable, innovative solutions that positively impact the drug development process, ultimately accelerating product entry into the market."
"How companies leverage new developments can help them break through process barriers to realize substantial competitive advantages," stated Metin Celik, Ph.D., president, PTI. "SommaTech and PTI, Inc. bring deep industry experience and technological innovation to help clients reduce the amount of time to reach peak sales."